Lung Cancer

Phase 3 trials confirm benefits for immune therapies in NSCLC

Overall survival is doubled in patients with metastatic NSCLC  treated with pembrolizumab in combination with chemotherapy compared to chemo alone, a phase 3 trial has confirmed. In findings released at the American Association for Cancer Research (AACR) annual meeting in Chicago, the KEYNOTE-189 study showed significant benefits for pembrolizumab combined with pemetrexed and a platinum-based drug ...

Already a member?

Login to keep reading.

© 2022 the limbic